Vancouver-based AI drug discovery company AbCellera Biologics, together with the governments of Canada and British Columbia (BC), is co-investing in a CAD 701 million (USD 516 million) project over a period of eight years to extend the capacity of the company's manufacturing plant with the aim of expanding the drug development and manufacturing capacity of the region.
AbCellera will inject CAD 401 million (USD 295 million) into the project while the governments of Canada and BC will invest CAD 225 million (USD 166 million) and CAD 75 million (USD 55 million), respectively.
The expanded facility, currently under construction, aims to expand the capabilities of Canada and BC in conducting research, discovering novel antibody therapies, and initiating preclinical development, all the way to conducting clinical trials. The facility is also expected to create more than 400 jobs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.